Gene Editing and Reprogramming of Human Fibroblast Cells to Human Induced Pluripotent Stem Cells
Author:
Zhang Zhe,Ding Shinghua
Reference35 articles.
1. Doss MX, Sachinidis A (2019) Current challenges of iPSC-based disease modeling and therapeutic implications. Cells 8:403
2. Gunaseeli I, Doss MX, Antzelevitch C, Hescheler J, Sachinidis A (2010) Induced pluripotent stem cells as a model for accelerated patient-and disease-specific drug discovery. Curr Med Chem 17:759–766
3. Wang Y, Liang P, Lan F et al (2014) Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol 64:451–459
4. Shi Y, Inoue H, Wu JC, Yamanaka S (2017) Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov 16:115–130
5. Liang P, Lan F, Lee AS, Gong T et al (2013) Drug screening using a library of human induced pluripotent stem cell–derived cardiomyocytes reveal disease-specific patterns of cardiotoxicity. Circulation 127:1677–1691